Michael P. Stern
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael P. Stern has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
Ken Williams
6 shared publications- Braxton D. Mitchell
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
4 shared publications Steven M. Haffner
Division of Clinical Epidemiology, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas
4 shared publications- John Blangero
The University of Texas Rio Grande Valley
3 shared publications - Jean W. MacCluer
Southwest Foundation for Biomedical Research, San Antonio, TX, USA
2 shared publications - John Blangero
Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, Texas, USA
2 shared publications
Latest Publications
- 29 February 2008
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 79 (2) , e14-e16
Genetic polymorphisms in the renin–angiotensin system (RAS) genes and their association analysis with type 2 diabetes and related traits in Mexican Americans
- 29 February 2008
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 79 (2) , e14-e16
Genetic polymorphisms in the renin–angiotensin system (RAS) genes and their association analysis with type 2 diabetes and related traits in Mexican Americans
- 1 August 2005
- Published by Elsevier in Kidney International
- Vol. 68 (97) , S34-S39
Microalbuminuria as a predictor of myocardial infarction in a Mexican population: The Mexico City Diabetes Study
- 1 August 2005
- Published by Elsevier in Kidney International
- Vol. 68 (97) , S34-S39
Microalbuminuria as a predictor of myocardial infarction in a Mexican population: The Mexico City Diabetes Study
- 1 May 2005
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 6 (2) , 3-6
Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease
- 1 May 2005
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 6 (2) , 3-6
Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease
- 1 February 2005
- Published by American Diabetes Association in Diabetes
- Vol. 54 (2) , 333-339
Identification of Individuals With Insulin Resistance Using Routine Clinical Measurements
Insulin resistance is a treatable precursor of diabetes and potentially of cardiovascular disease as well. To identify insulin-resistant patients, we developed decision rules from measurements of obesity, fasting glucose, insulin, lipids, and blood pressure and family history in 2,321 (2,138 nondiabetic) individuals studied with the euglycemic insulin clamp technique at 17 European sites; San Antonio, Texas; and the Pima Indian reservation. The distribution of whole-body glucose disposal appeared to be bimodal, with an optimal insulin resistance cutoff of 28.9 kg/m2, homeostasis model assessment of insulin resistance (HOMA-IR) >4.65, or BMI >27.5 kg/m2 and HOMA-IR >3.60. The fasting serum insulin concentrations corresponding to these HOMA-IR cut points were 20.7 and 16.3 μU/ml, respectively. This rule had a sensitivity and specificity of 84.9 and 78.7%, respectively. The second model, which included clinical measurements but no laboratory determinations, had an aROC of 85.0% and generated a decision rule that had a sensitivity and specificity of 78.7 and 79.6%, respectively. The third model, which included clinical measurements and lipid measurements but not insulin (and thus excluded HOMA-IR as well), had a similar aROC (85.1%), sensitivity (81.3%), and specificity (76.3%). Thus, insulin-resistant individuals can be identified using simple decision rules that can be tailored to specific needs.
- 1 February 2005
- Published by American Diabetes Association in Diabetes
- Vol. 54 (2) , 333-339
Identification of Individuals With Insulin Resistance Using Routine Clinical Measurements
Insulin resistance is a treatable precursor of diabetes and potentially of cardiovascular disease as well. To identify insulin-resistant patients, we developed decision rules from measurements of obesity, fasting glucose, insulin, lipids, and blood pressure and family history in 2,321 (2,138 nondiabetic) individuals studied with the euglycemic insulin clamp technique at 17 European sites; San Antonio, Texas; and the Pima Indian reservation. The distribution of whole-body glucose disposal appeared to be bimodal, with an optimal insulin resistance cutoff of 28.9 kg/m2, homeostasis model assessment of insulin resistance (HOMA-IR) >4.65, or BMI >27.5 kg/m2 and HOMA-IR >3.60. The fasting serum insulin concentrations corresponding to these HOMA-IR cut points were 20.7 and 16.3 μU/ml, respectively. This rule had a sensitivity and specificity of 84.9 and 78.7%, respectively. The second model, which included clinical measurements but no laboratory determinations, had an aROC of 85.0% and generated a decision rule that had a sensitivity and specificity of 78.7 and 79.6%, respectively. The third model, which included clinical measurements and lipid measurements but not insulin (and thus excluded HOMA-IR as well), had a similar aROC (85.1%), sensitivity (81.3%), and specificity (76.3%). Thus, insulin-resistant individuals can be identified using simple decision rules that can be tailored to specific needs.
- Open Access
- 1 November 2004
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (11) , 2676-2681
Does the Metabolic Syndrome Improve Identification of Individuals at Risk of Type 2 Diabetes and/or Cardiovascular Disease?
OBJECTIVE—The metabolic syndrome has been promoted as a method for identifying high-risk individuals for type 2 diabetes and cardiovascular disease (CVD). We therefore sought to compare this syndrome, as defined by the National Cholesterol Education Program, to the Diabetes Predicting Model and the Framingham Risk Score as predictors of type 2 diabetes and CVD, respectively. RESEARCH DESIGN AND METHODS—A population-based sample of 1,709 initially nondiabetic San Antonio Heart Study (SAHS) participants were followed for 7.5 years, 195 of whom developed type 2 diabetes. Over the same time interval, 156 of 2,570 SAHS participants experienced a cardiovascular event. A population-based sample of 1,353 initially nondiabetic Mexico City Diabetes Study (MCDS) participants were followed for 6.5 years, 125 of whom developed type 2 diabetes. Baseline measurements included medical history, age, sex, ethnicity, smoking status, BMI, blood pressure, fasting and 2-h plasma glucose levels, and fasting serum total and HDL cholesterol and triglycerides. RESULTS—The sensitivities for predicting diabetes with the metabolic syndrome were 66.2 and 62.4% in the SAHS and the MCDS, respectively, and the false-positive rates were 27.8 and 38.7%, respectively. The sensitivity and false-positive rates for predicting CVD with the metabolic syndrome in the SAHS were 67.3 and 34.2%, respectively. At corresponding false-positive rates, the two predicting models had significantly higher sensitivities and, at corresponding sensitivities, significantly lower false-positive rates than the metabolic syndrome for both end points. Combining the metabolic syndrome with either predicting model did not improve the prediction of either end point. CONCLUSIONS—The metabolic syndrome is inferior to established predicting models for either type 2 diabetes or CVD.
- 1 November 2004
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (11) , 2676-2681
Open AccessDoes the Metabolic Syndrome Improve Identification of Individuals at Risk of Type 2 Diabetes and/or Cardiovascular Disease?
OBJECTIVE—The metabolic syndrome has been promoted as a method for identifying high-risk individuals for type 2 diabetes and cardiovascular disease (CVD). We therefore sought to compare this syndrome, as defined by the National Cholesterol Education Program, to the Diabetes Predicting Model and the Framingham Risk Score as predictors of type 2 diabetes and CVD, respectively. RESEARCH DESIGN AND METHODS—A population-based sample of 1,709 initially nondiabetic San Antonio Heart Study (SAHS) participants were followed for 7.5 years, 195 of whom developed type 2 diabetes. Over the same time interval, 156 of 2,570 SAHS participants experienced a cardiovascular event. A population-based sample of 1,353 initially nondiabetic Mexico City Diabetes Study (MCDS) participants were followed for 6.5 years, 125 of whom developed type 2 diabetes. Baseline measurements included medical history, age, sex, ethnicity, smoking status, BMI, blood pressure, fasting and 2-h plasma glucose levels, and fasting serum total and HDL cholesterol and triglycerides. RESULTS—The sensitivities for predicting diabetes with the metabolic syndrome were 66.2 and 62.4% in the SAHS and the MCDS, respectively, and the false-positive rates were 27.8 and 38.7%, respectively. The sensitivity and false-positive rates for predicting CVD with the metabolic syndrome in the SAHS were 67.3 and 34.2%, respectively. At corresponding false-positive rates, the two predicting models had significantly higher sensitivities and, at corresponding sensitivities, significantly lower false-positive rates than the metabolic syndrome for both end points. Combining the metabolic syndrome with either predicting model did not improve the prediction of either end point. CONCLUSIONS—The metabolic syndrome is inferior to established predicting models for either type 2 diabetes or CVD.
- Open Access
- 31 December 2003
- Published by Springer Nature in BMC Genomic Data
- Vol. 4 (S1) , S52
Evidence for bivariate linkage of obesity and HDL-C levels in the Framingham Heart Study
Background: Epidemiological studies have indicated that obesity and low high-density lipoprotein (HDL) levels are strong cardiovascular risk factors, and that these traits are inversely correlated. Despite the belief that these traits are correlated in part due to pleiotropy, knowledge on specific genes commonly affecting obesity and dyslipidemia is very limited. To address this issue, we first conducted univariate multipoint linkage analysis for body mass index (BMI) and HDL-C to identify loci influencing variation in these phenotypes using Framingham Heart Study data relating to 1702 subjects distributed across 330 pedigrees. Subsequently, we performed bivariate multipoint linkage analysis to detect common loci influencing covariation between these two traits. Results: We scanned the genome and identified a major locus near marker D6S1009 influencing variation in BMI (LOD = 3.9) using the program SOLAR. We also identified a major locus for HDL-C near marker D2S1334 on chromosome 2 (LOD = 3.5) and another region near marker D6S1009 on chromosome 6 with suggestive evidence for linkage (LOD = 2.7). Since these two phenotypes have been independently mapped to the same region on chromosome 6q, we used the bivariate multipoint linkage approach using SOLAR. The bivariate linkage analysis of BMI and HDL-C implicated the genetic region near marker D6S1009 as harboring a major gene commonly influencing these phenotypes (bivariate LOD = 6.2; LODeq = 5.5) and appears to improve power to map the correlated traits to a region, precisely. Conclusions: We found substantial evidence for a quantitative trait locus with pleiotropic effects, which appears to influence both BMI and HDL-C phenotypes in the Framingham data.
- 31 December 2003
- Published by Springer Nature in BMC Genomic Data
- Vol. 4 (S1) , S52
Open AccessEvidence for bivariate linkage of obesity and HDL-C levels in the Framingham Heart Study
Background: Epidemiological studies have indicated that obesity and low high-density lipoprotein (HDL) levels are strong cardiovascular risk factors, and that these traits are inversely correlated. Despite the belief that these traits are correlated in part due to pleiotropy, knowledge on specific genes commonly affecting obesity and dyslipidemia is very limited. To address this issue, we first conducted univariate multipoint linkage analysis for body mass index (BMI) and HDL-C to identify loci influencing variation in these phenotypes using Framingham Heart Study data relating to 1702 subjects distributed across 330 pedigrees. Subsequently, we performed bivariate multipoint linkage analysis to detect common loci influencing covariation between these two traits. Results: We scanned the genome and identified a major locus near marker D6S1009 influencing variation in BMI (LOD = 3.9) using the program SOLAR. We also identified a major locus for HDL-C near marker D2S1334 on chromosome 2 (LOD = 3.5) and another region near marker D6S1009 on chromosome 6 with suggestive evidence for linkage (LOD = 2.7). Since these two phenotypes have been independently mapped to the same region on chromosome 6q, we used the bivariate multipoint linkage approach using SOLAR. The bivariate linkage analysis of BMI and HDL-C implicated the genetic region near marker D6S1009 as harboring a major gene commonly influencing these phenotypes (bivariate LOD = 6.2; LODeq = 5.5) and appears to improve power to map the correlated traits to a region, precisely. Conclusions: We found substantial evidence for a quantitative trait locus with pleiotropic effects, which appears to influence both BMI and HDL-C phenotypes in the Framingham data.
- 17 March 2003
- Published by Wiley in Genetic Epidemiology
- Vol. 24 (3) , 240-242
Further evidence for a type 2 diabetes susceptibility locus on chromosome 11q
- 17 March 2003
- Published by Wiley in Genetic Epidemiology
- Vol. 24 (3) , 240-242
Further evidence for a type 2 diabetes susceptibility locus on chromosome 11q
- Open Access
- 1 March 2003
- Published by American Diabetes Association in Diabetes Care
- Vol. 26 (3) , 940-941
Do We Need the Oral Glucose Tolerance Test to Identify Future Cases of Type 2 Diabetes?
In our recent article (1), in which we presented a predicting model based on readily available clinical variables for identifying individuals at high risk of future type 2 diabetes, we concluded with the words: “… we hope that this report will stimulate other researchers with suitable databases to evaluate (similar) prediction models… ” The first group to take up this challenge is McNeely et al. (2), whose report appears in this issue of Diabetes Care . The results of their analyses in Japanese Americans raise the interesting possibility that the predicting model performs better in younger than older individuals. A major difference between the Japanese-American cohort and our San Antonio cohort was the older age range of the former (34–75 years, mean ∼52 vs. 25–64, mean 43.5). One reason why 2-h glucose might play a larger role in predicting future diabetes in older subjects is that the other risk factors for diabetes, notably, lipids and blood pressure, are also risk factors for cardiovascular disease. Thus, the older the cohort, the greater the likelihood that individuals with risk factors will fail to return for follow-up glucose tolerance testing as a result of having developed either cardiovascular morbidity or mortality. It thus becomes less likely that these same risk factors will emerge as predictive of diabetes. The finding by McNeely et al. that BMI is a stronger risk factor in individuals <55 years of age supports this concept. Based on their suggestion, we have reanalyzed our data and have also observed an interaction in the same direction between age and BMI. McNeely et al. also observed an interaction between age and HDL, although we did not. All of the above points notwithstanding, however, it must be acknowledged that the fact that only eight individuals in the study by McNeely et al. died …
- 1 March 2003
- Published by American Diabetes Association in Diabetes Care
- Vol. 26 (3) , 940-941
Open AccessDo We Need the Oral Glucose Tolerance Test to Identify Future Cases of Type 2 Diabetes?
In our recent article (1), in which we presented a predicting model based on readily available clinical variables for identifying individuals at high risk of future type 2 diabetes, we concluded with the words: “… we hope that this report will stimulate other researchers with suitable databases to evaluate (similar) prediction models… ” The first group to take up this challenge is McNeely et al. (2), whose report appears in this issue of Diabetes Care . The results of their analyses in Japanese Americans raise the interesting possibility that the predicting model performs better in younger than older individuals. A major difference between the Japanese-American cohort and our San Antonio cohort was the older age range of the former (34–75 years, mean ∼52 vs. 25–64, mean 43.5). One reason why 2-h glucose might play a larger role in predicting future diabetes in older subjects is that the other risk factors for diabetes, notably, lipids and blood pressure, are also risk factors for cardiovascular disease. Thus, the older the cohort, the greater the likelihood that individuals with risk factors will fail to return for follow-up glucose tolerance testing as a result of having developed either cardiovascular morbidity or mortality. It thus becomes less likely that these same risk factors will emerge as predictive of diabetes. The finding by McNeely et al. that BMI is a stronger risk factor in individuals <55 years of age supports this concept. Based on their suggestion, we have reanalyzed our data and have also observed an interaction in the same direction between age and BMI. McNeely et al. also observed an interaction between age and HDL, although we did not. All of the above points notwithstanding, however, it must be acknowledged that the fact that only eight individuals in the study by McNeely et al. died …
- 1 October 2002
- Published by American Diabetes Association in Diabetes Care
- Vol. 25 (10) , 1851-1856
Predicting Future Cardiovascular Disease
OBJECTIVE—Our objective was to compare the performance of oral glucose tolerance tests (OGTTs) and multivariate models incorporating commonly available clinical variables in their ability to predict future cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS—We randomly selected 2,662 Mexican-Americans and 1,595 non-Hispanic whites, 25–64 years of age, who were free of both CVD and known diabetes at baseline from several San Antonio census tracts. Medical history, cigarette smoking history, BMI, blood pressure, fasting and 2-h plasma glucose and serum insulin levels, triglyceride level, and fasting serum total, LDL, and HDL cholesterol levels were obtained at baseline. CVD developed in 88 Mexican-Americans and 71 non-Hispanic whites after 7–8 years of follow-up. Stepwise multiple logistic regression models were developed to predict incident CVD. The areas under receiver operator characteristic (ROC) curves were used to assess the predictive power of these models. RESULTS—The area under the 2-h glucose ROC curve was modestly but not significantly greater than under the fasting glucose curve, but both were relatively weak predictors of CVD. The areas under the ROC curves for the multivariate models incorporating readily available clinical variables other than 2-h glucose were substantially and significantly greater than under the glucose ROC curves. Addition of 2-h glucose to these models did not improve their predicting power. CONCLUSIONS—Better identification of individuals at high risk for CVD can be achieved with simple predicting models than with OGTTs, and the addition of the latter adds little if anything to the predictive power of the model.
- 1 October 2002
- Published by American Diabetes Association in Diabetes Care
- Vol. 25 (10) , 1851-1856
Predicting Future Cardiovascular Disease
OBJECTIVE—Our objective was to compare the performance of oral glucose tolerance tests (OGTTs) and multivariate models incorporating commonly available clinical variables in their ability to predict future cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS—We randomly selected 2,662 Mexican-Americans and 1,595 non-Hispanic whites, 25–64 years of age, who were free of both CVD and known diabetes at baseline from several San Antonio census tracts. Medical history, cigarette smoking history, BMI, blood pressure, fasting and 2-h plasma glucose and serum insulin levels, triglyceride level, and fasting serum total, LDL, and HDL cholesterol levels were obtained at baseline. CVD developed in 88 Mexican-Americans and 71 non-Hispanic whites after 7–8 years of follow-up. Stepwise multiple logistic regression models were developed to predict incident CVD. The areas under receiver operator characteristic (ROC) curves were used to assess the predictive power of these models. RESULTS—The area under the 2-h glucose ROC curve was modestly but not significantly greater than under the fasting glucose curve, but both were relatively weak predictors of CVD. The areas under the ROC curves for the multivariate models incorporating readily available clinical variables other than 2-h glucose were substantially and significantly greater than under the glucose ROC curves. Addition of 2-h glucose to these models did not improve their predicting power. CONCLUSIONS—Better identification of individuals at high risk for CVD can be achieved with simple predicting models than with OGTTs, and the addition of the latter adds little if anything to the predictive power of the model.
- 16 April 2002
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 136 (8) , 575-581
Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test?
The standard method of identifying persons at high risk for type 2 diabetes mellitus involves detection of impaired glucose tolerance, which requires a costly and inconvenient 2-hour oral glucose tolerance test. Because clinical trials have indicated that diabetes is preventable by using behavioral or pharmacologic interventions, less expensive methods of identifying high-risk persons are needed. To determine whether multivariable models are superior to glucose tolerance tests for identifying persons at high risk for diabetes mellitus. Prospective cohort study. San Antonio, Texas. 1791 Mexican Americans and 1112 non-Hispanic whites without diabetes at baseline who were randomly selected from census tracts. Medical history; body mass index; blood pressure; fasting and 2-hour plasma glucose levels; fasting serum total, low-density lipoprotein, and high-density lipoprotein cholesterol levels; and triglyceride level. For prediction of 7.5-year incidence of type 2 diabetes, the area under the receiver-operating characteristic (ROC) curve for a multivariable model involving readily available clinical variables was significantly (P < 0.001) greater than the area under the ROC curve for the 2-hour glucose value alone (84.3% vs. 77.5%). Impaired glucose tolerance represents a single point on the latter curve. Adding the 2-hour glucose measurement to the multivariable model increased the area under its ROC curve, but only from 84.3% to 85.7%. Persons at high risk for diabetes mellitus are better identified by using a simple prediction model than by relying exclusively on the results of a 2-hour oral glucose tolerance test. Although adding the 2-hour glucose variable to the model enhanced prediction, the resulting slight improvement entails greater cost and inconvenience.
- 16 April 2002
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 136 (8) , 575-581
Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test?
The standard method of identifying persons at high risk for type 2 diabetes mellitus involves detection of impaired glucose tolerance, which requires a costly and inconvenient 2-hour oral glucose tolerance test. Because clinical trials have indicated that diabetes is preventable by using behavioral or pharmacologic interventions, less expensive methods of identifying high-risk persons are needed. To determine whether multivariable models are superior to glucose tolerance tests for identifying persons at high risk for diabetes mellitus. Prospective cohort study. San Antonio, Texas. 1791 Mexican Americans and 1112 non-Hispanic whites without diabetes at baseline who were randomly selected from census tracts. Medical history; body mass index; blood pressure; fasting and 2-hour plasma glucose levels; fasting serum total, low-density lipoprotein, and high-density lipoprotein cholesterol levels; and triglyceride level. For prediction of 7.5-year incidence of type 2 diabetes, the area under the receiver-operating characteristic (ROC) curve for a multivariable model involving readily available clinical variables was significantly (P < 0.001) greater than the area under the ROC curve for the 2-hour glucose value alone (84.3% vs. 77.5%). Impaired glucose tolerance represents a single point on the latter curve. Adding the 2-hour glucose measurement to the multivariable model increased the area under its ROC curve, but only from 84.3% to 85.7%. Persons at high risk for diabetes mellitus are better identified by using a simple prediction model than by relying exclusively on the results of a 2-hour oral glucose tolerance test. Although adding the 2-hour glucose variable to the model enhanced prediction, the resulting slight improvement entails greater cost and inconvenience.